IBDEI04O ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1661,1,3,0)
 ;;=3^Benign paroxysmal vertigo, bilateral
 ;;^UTILITY(U,$J,358.3,1661,1,4,0)
 ;;=4^H81.13
 ;;^UTILITY(U,$J,358.3,1661,2)
 ;;=^5006867
 ;;^UTILITY(U,$J,358.3,1662,0)
 ;;=H81.11^^3^46^15
 ;;^UTILITY(U,$J,358.3,1662,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1662,1,3,0)
 ;;=3^Benign paroxysmal vertigo, right ear
 ;;^UTILITY(U,$J,358.3,1662,1,4,0)
 ;;=4^H81.11
 ;;^UTILITY(U,$J,358.3,1662,2)
 ;;=^5006865
 ;;^UTILITY(U,$J,358.3,1663,0)
 ;;=H81.12^^3^46^14
 ;;^UTILITY(U,$J,358.3,1663,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1663,1,3,0)
 ;;=3^Benign paroxysmal vertigo, left ear
 ;;^UTILITY(U,$J,358.3,1663,1,4,0)
 ;;=4^H81.12
 ;;^UTILITY(U,$J,358.3,1663,2)
 ;;=^5006866
 ;;^UTILITY(U,$J,358.3,1664,0)
 ;;=I63.50^^3^46^16
 ;;^UTILITY(U,$J,358.3,1664,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1664,1,3,0)
 ;;=3^Cereb infrc due to unsp occls or stenos of unsp cereb artery
 ;;^UTILITY(U,$J,358.3,1664,1,4,0)
 ;;=4^I63.50
 ;;^UTILITY(U,$J,358.3,1664,2)
 ;;=^5007343
 ;;^UTILITY(U,$J,358.3,1665,0)
 ;;=G45.9^^3^46^63
 ;;^UTILITY(U,$J,358.3,1665,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1665,1,3,0)
 ;;=3^Transient cerebral ischemic attack, unspecified
 ;;^UTILITY(U,$J,358.3,1665,1,4,0)
 ;;=4^G45.9
 ;;^UTILITY(U,$J,358.3,1665,2)
 ;;=^5003959
 ;;^UTILITY(U,$J,358.3,1666,0)
 ;;=I67.9^^3^46^17
 ;;^UTILITY(U,$J,358.3,1666,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1666,1,3,0)
 ;;=3^Cerebrovascular disease, unspecified
 ;;^UTILITY(U,$J,358.3,1666,1,4,0)
 ;;=4^I67.9
 ;;^UTILITY(U,$J,358.3,1666,2)
 ;;=^5007389
 ;;^UTILITY(U,$J,358.3,1667,0)
 ;;=I69.91^^3^46^18
 ;;^UTILITY(U,$J,358.3,1667,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1667,1,3,0)
 ;;=3^Cognitive deficits following unsp cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,1667,1,4,0)
 ;;=4^I69.91
 ;;^UTILITY(U,$J,358.3,1667,2)
 ;;=^5007552
 ;;^UTILITY(U,$J,358.3,1668,0)
 ;;=I69.920^^3^46^9
 ;;^UTILITY(U,$J,358.3,1668,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1668,1,3,0)
 ;;=3^Aphasia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,1668,1,4,0)
 ;;=4^I69.920
 ;;^UTILITY(U,$J,358.3,1668,2)
 ;;=^5007553
 ;;^UTILITY(U,$J,358.3,1669,0)
 ;;=I69.921^^3^46^27
 ;;^UTILITY(U,$J,358.3,1669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1669,1,3,0)
 ;;=3^Dysphasia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,1669,1,4,0)
 ;;=4^I69.921
 ;;^UTILITY(U,$J,358.3,1669,2)
 ;;=^5007554
 ;;^UTILITY(U,$J,358.3,1670,0)
 ;;=I69.951^^3^46^33
 ;;^UTILITY(U,$J,358.3,1670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1670,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff right dominant side
 ;;^UTILITY(U,$J,358.3,1670,1,4,0)
 ;;=4^I69.951
 ;;^UTILITY(U,$J,358.3,1670,2)
 ;;=^5007561
 ;;^UTILITY(U,$J,358.3,1671,0)
 ;;=I69.952^^3^46^34
 ;;^UTILITY(U,$J,358.3,1671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1671,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff left dominant side
 ;;^UTILITY(U,$J,358.3,1671,1,4,0)
 ;;=4^I69.952
 ;;^UTILITY(U,$J,358.3,1671,2)
 ;;=^5133586
 ;;^UTILITY(U,$J,358.3,1672,0)
 ;;=I69.953^^3^46^35
 ;;^UTILITY(U,$J,358.3,1672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1672,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff right nondom side
 ;;^UTILITY(U,$J,358.3,1672,1,4,0)
 ;;=4^I69.953
 ;;^UTILITY(U,$J,358.3,1672,2)
 ;;=^5007562
 ;;^UTILITY(U,$J,358.3,1673,0)
 ;;=I69.954^^3^46^36
 ;;^UTILITY(U,$J,358.3,1673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1673,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff left nondom side
 ;;
 ;;$END ROU IBDEI04O
